Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation (PODD) Free cash flow
Insulet Corporation's free cash flow for fiscal 2025 was $349.9M, up 18.1% from $296.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $265.6M. Over the past ten years it has ranged from −$190.8M (fiscal 2021) to $349.9M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 4 consecutive fiscal years. Insulet Corporation ranks 16th of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $349.9M | 18.13% |
| FY2024 | $296.2M | 711.51% |
| FY2023 | $36.5M | — |
| FY2022 | −$38.3M | — |
| FY2021 | −$190.8M | — |
| FY2020 | −$82.5M | — |
| FY2019 | −$72.5M | — |
| FY2018 | −$126.5M | — |
| FY2017 | −$35.9M | — |
| FY2016 | −$6.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $51.1M | (40.58%) |
| Mar 2026 | $86.0M | 153.69% |
| Dec 2025 | $33.9M | (64.16%) |
| Sep 2025 | $94.6M | (45.41%) |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.0B |
| GMED Globus Medical, Inc. compare | $755.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $353.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $353.1M |
| HAE Haemonetics Corporation compare | $292.5M |
| PODD Insulet Corporation | $265.6M |
| PEN Penumbra, Inc. compare | $215.9M |
| BRKR Bruker Corporation compare | $93.9M |
| GKOS Glaukos Corporation compare | −$12.2M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement